Aim: To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong.
acid analogue trifluridine/tipiracil (TAS-102). Still, the treatment patterns and outcomes beyond PD2 in the local population remain largely unknown.
Two clinical questions were of particular interest. The first question related to the optimal treatment choice and sequence at the refractory mCRC setting. Treatment options for refractory mCRC include:
(1) the oral multikinase inhibitor regorafenib, which blocks the activity of protein kinases involved in tumor angiogenesis (including VEGF receptors 1-3), oncogenesis (including BRAF V600E and RAF-1) and the tumor microenvironment (including platelet-derived growth factor receptor and fibroblast growth factor receptor); 7, 8 (2) the oral combination drug TAS-102, which contains the cytotoxic thymidinebased nucleic acid analogue trifluridine and a thymidine phosphorylase inhibitor, tipiracil hydrochloride; 9 and (3) "rechallenge" with prior chemotherapy and/or targeted therapy. 5, 10, 11 To our knowledge, no randomized clinical trial has directly compared these options or different sequences for their use. Studies have reported similar efficacies and different toxicity profiles for regorafenib and TAS-102. 12, 13 Regorafenib has been favored for patients aged <65 years and TAS-102 for those aged ≥ 65. 14 An understanding of the real-world patterns and outcomes for these agents would allow optimization of the choice and sequencing of each for therapy. The second question was what are the main survival predictors for refractory mCRC? Many refractory mCRC patients will have experienced deteriorations in physical health and the toxicities of prior therapies, for whom symptom control and quality of life are important considerations. 15 Presumably, some of these patients would also be deemed ineligible for treatments being tested in clinical trials. It would be helpful to further observe objectively the predictors of overall survival (OS) among these patients, and to understand factors that might affect their choice of active therapy versus palliative care.
The primary objective of this study was to evaluate the OS beyond PD2; potential prognostic factors were analyzed using the Cox proportional hazards model. The secondary objective was to compare the frequencies and outcomes of active treatment in patients who were and were not deemed eligible for clinical trials under similar settings (Online Appendix A). We hope that this study will provide insights into the optimization of patient selection and treatment strategy in the real-world setting.
METHODS
The clinical records of all mCRC patients who were treated beyond The primary endpoints were time from the date of PD2 to death (OS-PD2) and time from the first dose of 3L treatment to death (OS-3L+). The use of OS-PD2 allows for a uniform outcome assessment in patients receiving 3L active treatment versus those receiving palliative care, whereas that of OS-3L+ allows for an accurate assessment of clinical benefits derived from specific active treatment regimens. The secondary endpoints were progression-free survival (PFS) and toxicities for the active treatment. PFS was reported only in those who received active 3L treatment because patients on palliative care alone in the community setting would not have had regular imaging reassessment to determine the date of progression. Hence, PFS was defined as the time from the start of active 3L treatment to the first event of clinical or radiographic progression or death. 
RESULTS

Patient demographics
Treatment outcomes for the entire cohort, active treatment versus palliative care after PD2
The median OS from PD2 (OS-PD2) for the entire cohort was 6.7 months (95% CI: 5.9-7.5). The 6-month and 1-year survival rates were 56.6% and 27.5%, respectively ( Figure 1A ). Seventy-two patients (40.9%) underwent active 3L treatment (Table 2) 
Patients on 3L+ active treatment: outcomes and prognostic factors
In the univariate analysis of patients who underwent active 3L treatment (Table 3) Among patients who received various 3L regimens, those who received chemotherapy plus anti-VEGF therapy had the best median OS (11.7 months), followed by chemotherapy plus anti-EGFR therapy (8.1 months), regorafenib (5.7 months) and TAS-102 (5.4 months) ( Table 2 ). Multivariate analysis ( Table 3 ) also showed that chemotherapy plus anti-VEGF therapy was prognostic to survival when compared to TAS-102 (HR = 4.33, 95% CI: 1.51-12.43; P = 0.006), but not significant when compared to chemotherapy plus anti-EGFR therapy (P = 0.28) or regorafenib (P = 0.07). A similar trend was observed in predictors of PFS: chemotherapy plus anti-VEGF therapy was prognostic to PFS when compared to regorafenib (HR = 2.26, 95% CI: 1.24-4.10; P = 0.008), but not significant when compared to chemotherapy plus anti-EGFR therapy (P = 0.58) or TAS-102 (P = 0.46). The baseline characteristics of patients put on active 3L treatments are detailed in Supplementary Table S1 . 
Treatment pattern versus eligibility to active treatment
The relationship between treatment eligibility according to common mCRC clinical trial inclusion and exclusion criteria (see Online Appendix A) and real-world treatment patterns was also investigated (Table 4) . Sixty-two percent (109 out of 176) of patients were deemed eligible for active treatment, while the remaining 38% were ineligible mainly due to ECOG performance status > 1 (23.3%), hepatitis B carrier (5.1%) and hemoglobin < 9 g/dL (5.1%). Notably, 50% of the eligible patients were put on palliative care, while 25% of ineligible individuals received active 3L treatment. Trial eligible patients had better OS than trial ineligible patients (8.3 vs 5.6 months, P < 0.001; Figure 1D ).
The results also showed that both clinical trial eligible and ineligible patients achieved better OS with active 3L+ treatment versus palliative care only (eligible: 12.1 vs 6.4 months, P < 0.001; ineligible: 8.2 vs 4.4 months, P = 0.002; Table 4 ).
Safety of active treatment
The adverse events are reported in Supplementary Table S2 . The most common ≥ grade 3 toxicities observed were as follows: 
DISCUSSION
In our opinion, the results of the present study could be considered highly illustrative of the treatment patterns and outcomes of refractory mCRC in several regards: (1) predictors of OS; (2) treatment eligibility; and (3) OS for different therapies in the real-world setting.
First, among our patients who underwent active 3L treatment, the most significant predictors of OS were the time from diagnosis of metastasis to PD2 and whether or not the patients received post-3L therapy. These factors could be indicative of the efficacy and duration of therapies (if any), biological aggressiveness of the tumor or both. Our findings are consistent with previous reports suggesting that the tempo of progression, and 1L-and 2L-treatment duration, are important determinants of survival in heavily pretreated mCRC patients. 16, 17 Maximizing the exposure of active agents has been the cornerstone strategy to improving mCRC patient outcomes. 18 Previous registration trials have confirmed the benefit of treatment in the refractory setting, such that regorafenib or TAS-102 can benefit patients who received ≥ 3 lines of therapy, 9, 19 and a substantial proportion of patients can have disease control with TAS-102 after regorafenib exposure. 20 In the current study, patients who received post-3L therapy had better OS than those who stopped after 3L treatment (15.1 vs 6.0 months, HR = 0.41, P = 0.002). Among six patients who were exposed to both regorafenib and TAS-102 as salvage treatment, the median OS was 15.4 (95% CI: 3.1-27.6) months (data not shown).
Taken together, these results suggest that, among heavily pretreated patients in satisfactory clinical condition, optimizing the exposure of active agents is imperative for maximizing survival.
Surprisingly, ECOG performance status (0-1 vs ≥ 2) and the number and location of metastases, factors that were expected to be of high prognostic significance, 17 were nonsignificant in the multivariate analysis of patients on active treatment. Notably, while primary tumor location (PTL) has been shown to be prognostic in mCRC patients who received 1L therapy, [21] [22] [23] there was no difference in OS between leftside and right-side tumors (7.0 vs 6.0 months, respectively, P = 0.13) in our study. Similarly, Arora et al. 24 showed that, among 112 refractory mCRC patients who enrolled in a phase I trial, PTL was not predictive of survival (left: 6.6 months vs right: 5.9 months, P = 0.18 Table 4 ). Tomita et al. 27 observed an improved median OS associated with increased access to 1L bevacizumab use; however, the authors also noted that comorbidities, age and tumor location were likely among the factors that deterred use of the drug. In our study, proper counseling, improved access to medication and financial assistance, if available, could have been conducive toward better treatment outcomes.
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On the other hand, 25% of patients who would have been deemed ineligible for treatment in a trial setting underwent active 3L treatment and achieved better OS than those who received palliative care only (8.2 vs 4.4 months, P = 0.002), without major unexpected toxicity.
The stringent trial eligibility criteria may disqualify the majority of realworld refractory mCRC patients from active therapy. 28 In this study, despite the fact that 38% of the patients would have been considered trial ineligible, a proportion did benefit from active treatment, implying that physician discretion for patient suitability for treatment could be an important factor for optimizing treatment outcomes. This also highlights the importance of real-world data in modifying the application of clinical trial results.
Regarding the comparison of various 3L regimens, at first glance, the median OS of patients who received chemotherapy plus monoclonal antibodies appeared to exceed those who received regorafenib or TAS-102 (Table 2) . However, such results should be interpreted with caution. There was an imbalance in their baseline prognostic features (Supplementary Table S1 
CONCLUSIONS
The efficacy of late-line treatment for mCRC is well established, but discrepancies exist in translating this benefit into the real-world setting. This study echoed such discrepancies, showing that 3L therapy improved outcomes irrespective of a patient's overall eligibility for clinical trial. Our results emphasize the role of patient selection that properly maximizes treatment exposure for improved clinical outcomes.
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